China Securities Journal - China Securities Network (Wang Luo) — Recently, the award ceremony for the "19th Pharmaceutical Development Award" was held in Beijing. Liu Jiankai, a Director and Vice President of Kangtai Biological and the Executive Deputy General Manager of Beijing Minhai Biological Technology Co., Ltd. (hereinafter referred to as "Minhai Biological"), was honored with the "Outstanding Achievement Award." It is understood that the Pharmaceutical Development Award is a medical science award established in 1994, primarily recognizing outstanding scientific and technological talents who have achieved breakthrough innovative results in the medical and health fields.

Following the award ceremony, multiple academic exchange sessions were held. Among them, the Vaccine Innovation Forum, themed "Focusing on Frontiers, Interdisciplinary Integration, and Translational Application," was co-organized by Minhai Biological, a wholly-owned subsidiary of Kangtai Biological. The academic event brought together experts including academicians of the Chinese Academy of Engineering, renowned scholars from universities, specialists in the medical field, and industry representatives.

During the forum, Zhang Gaiping, an academician of the Chinese Academy of Engineering and a professor at Peking University, delivered an academic presentation titled "My Perspective on Vaccines." Zheng Sujun, Director of the First Department of the Liver Disease Center at Beijing You'an Hospital affiliated with Capital Medical University and a doctoral supervisor, together with Lin Ang, Director of the Pathogen Diagnosis and Vaccine Technology Innovation Center at China Pharmaceutical University, elaborated on the critical role of the hepatitis B vaccine in the treatment of chronic hepatitis B from the perspectives of clinical application value and R&D innovation progress. Zhang Yuntao, Chief Scientist and Vice President of China National Biotec Group, analyzed the current development status of the domestic and international vaccine industry in his report titled "Innovative Development of Chinese Vaccines." He systematically outlined the emerging R&D trends in China's vaccine sector, emphasizing that multivalent combination vaccines remain a key direction for the future development of the vaccine industry.

Liu Jiankai shared insights into the technological innovation of the double-carrier 13-valent pneumococcal vaccine and discussed the future development direction of pneumococcal vaccine technology. Yin Siyuan, Chief Operating Officer of Chuanxin Biotech, provided a detailed introduction to the research progress in cancer vaccines based on tumor-associated antigens, sparking deep reflection and lively discussion among the attending experts and scholars.

It is understood that since its establishment, Minhai Biological has consistently adhered to the mission of "Healthy China" through innovative research and development. The company has undertaken nine national scientific research projects (or topics) from the Ministry of Science and Technology, the Ministry of Industry and Information Technology, and the National Development and Reform Commission, and has received four provincial and ministerial-level science and technology awards, including the Beijing Science and Technology Progress Second Prize. It has successfully developed, industrialized, and launched 12 vaccine products. Among these, its quadrivalent combination vaccine is the first of its kind in China, and its double-carrier 13-valent pneumococcal conjugate vaccine is the world's first. The standards for both products have been incorporated into the Chinese Pharmacopoeia (Part III). The company has also adopted a forward-looking strategic approach in the R&D of world-first innovative vaccines products, such as a super-resistant Klebsiella pneumoniae vaccine, a DTaP-Hib-sIPV (pentavalent combination) vaccine, and a Class 1 novel tetravalent inactivated enterovirus vaccine, and has already established the foundational research and development framework for a DTaP-Hib-sIPV-HepB (hexavalent combination) vaccine.

Minhai Biological stated that this year, the company has also initiated the development of the first vaccine aimed at preventing recurrence in treated hepatitis B patients, marking its official entry into the multi-billion-yuan hepatitis B treatment market. This positions the company to potentially become one of China's leading enterprises covering the entire hepatitis B spectrum—from prevention and treatment to recurrence prevention.

Reference：https://finance.eastmoney.com/a/202512033581387950.html